Is the test appropriate for diagnoses of noninvasive carcinoma (ie, DCIS or LCIS)?

The HERmark Breast Cancer Assay has been prospectively analyzed in archived tumor specimens that are invasive carcinoma. There are no data on ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).

Weight: 
-4